12:00 AM
Jun 01, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

VX-770: Phase III start

This quarter, Vertex will begin a 2-part, double-blind, international Phase III trial to evaluate oral VX-770 in patients ages 6-11 carrying the G551D mutation in CFTR on at least 1 allele. The first part of the...

Read the full 156 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >